Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA-topoisomerase inhibitors

M D'Incalci1

  • 1Laboratory of Cancer Chemotherapy, Mario Negri Institute, Milan, Italy.

Current Opinion in Oncology
|November 1, 1993
PubMed
Summary

DNA topoisomerase enzymes regulate DNA topology. Anticancer drugs targeting these enzymes, like topoisomerase I and II inhibitors, offer novel therapeutic strategies by inducing DNA breaks or inhibiting enzyme activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

ESMO open·2026
Same author

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025
Same author

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023
Same author

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

ESMO open·2022
Same author

Corrigendum to 'COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)': [ESMO Open Volume 6, Issue 3, June 2021, 100165].

ESMO open·2021
Same author

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

ESMO open·2021

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • DNA topology is crucial for cellular processes and is regulated by DNA topoisomerase enzymes.
  • Topoisomerase I and II enzymes introduce transient single-strand and double-strand DNA breaks, respectively.
  • Many anticancer drugs function by interacting with these topoisomerase enzymes.

Purpose of the Study:

  • To elucidate the mechanisms of action for various topoisomerase inhibitors.
  • To understand the role of topoisomerase enzymes in mediating the effects of anticancer drugs.
  • To explore the basis of cellular resistance to topoisomerase inhibitors.

Main Methods:

  • Analysis of DNA-topoisomerase interactions.
  • Investigating drug-induced DNA-enzyme complex formation.
  • Studying the effects of topoisomerase inhibition on transcription and DNA replication.
  • Examining sequence specificity of DNA cleavage induced by drugs.

Main Results:

  • Anticancer drugs like anthracyclines and camptothecins target topoisomerase II alpha and topoisomerase I, respectively.
  • Some novel inhibitors block catalytic activity without forming complexes.
  • Inhibition of transcription and replication are key cytotoxic mechanisms.
  • Drug-induced DNA cleavage exhibits sequence specificity, influencing pharmacologic effects.

Conclusions:

  • Topoisomerase inhibitors represent a significant class of anticancer agents.
  • Understanding drug-enzyme interactions and resistance mechanisms is vital for optimizing cancer therapy.
  • Combinations of topoisomerase inhibitors and radiotherapy show sequence-dependent synergy.

Related Experiment Videos